Spots Global Cancer Trial Database for ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
Official Title: A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Study ID: NCT04829604
Conditions
Interventions
Study Description
Brief Summary: A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd
Detailed Description: A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients who were previously treated with T-DXd. The ARX788 will be administered every 3 weeks (Q3W) intravenous (IV) infusion.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Los Angeles, California, United States
Research Site, Los Angeles, California, United States
Research Site, Newport Beach, California, United States
Research Site, San Francisco, California, United States
Research Site, Santa Barbara, California, United States
Research Site, Torrance, California, United States
Research Site, West Los Angeles, California, United States
Research Site, Whittier, California, United States
Research Site, Newark, Delaware, United States
Research Site, Hollywood, Florida, United States
Research Site, Orlando, Florida, United States
Research Site, Athens, Georgia, United States
Research Site, Atlanta, Georgia, United States
Research Site, Chicago, Illinois, United States
Research Site, Louisville, Kentucky, United States
Research Site, Baton Rouge, Louisiana, United States
Research Site, Lutherville, Maryland, United States
Research Site, Silver Spring, Maryland, United States
Research Site, Boston, Massachusetts, United States
Research Site, Bolivar, Missouri, United States
Research Site, Saint Louis, Missouri, United States
Research Site, Omaha, Nebraska, United States
Research Site, Las Vegas, Nevada, United States
Research Site, Albuquerque, New Mexico, United States
Research Site, New York, New York, United States
Research Site, New York, New York, United States
Research Site, Portland, Oregon, United States
Research Site, Tigard, Oregon, United States
Research Site, Chattanooga, Tennessee, United States
Research Site, Nashville, Tennessee, United States
Research Site, Austin, Texas, United States
Research Site, Dallas, Texas, United States
Research Site, Houston, Texas, United States
Research Site, Plano, Texas, United States
Research Site, Tyler, Texas, United States
Research Site, Norfolk, Virginia, United States
Research Site, Tacoma, Washington, United States
Research Site, South Brisbane, Queensland, Australia
Research Site, Woolloongabba, Queensland, Australia
Research Site, Clayton, Victoria, Australia
Research Site, Frankston, Victoria, Australia
Research Site, Geelong, Victoria, Australia
Research Site, Melbourne, Victoria, Australia
Research Site, Ringwood East, Victoria, Australia
Research Site, Nedlands, Western Australia, Australia
Research Site, Avignon Cedex 09, , France
Research Site, La Rochelle, , France
Research Site, Le Mans, , France
Research Site, Nice, , France
Research Site, Toulouse CEDEX 9, , France
Research Site, Daegu, , Korea, Republic of
Research Site, Goyang-si, , Korea, Republic of
Research Site, Seongnam-si, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Seoul, , Korea, Republic of
Research Site, Suwon, , Korea, Republic of
Contact Details
Name: Ambrx
Affiliation: Ambrx, Inc.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
